Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions

R Leibowitz–Amit, AM Joshua - Current Oncology, 2012 - mdpi.com
Since the year 2000, tremendous progress has been made in the understanding of
castration-resistant prostate cancer (CRPC), a disease state now recognized to retain …
被引用次数：57 相关文章

Targeting the Androgen Receptor in the Management of Castration-Resistant Prostate Cancer: Rationale, Progress, and Future Directions

R Leibowitz–Amit, AM Joshua - Current Oncology, 2012 - cir.nii.ac.jp
抄録< jats: p> Since the year 2000, tremendous progress has been made in the
understanding of castration-resistant prostate cancer (CRPC), a disease state now …
[HTML] nih.gov

[HTML][HTML] Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions

R Leibowitz–Amit, AM Joshua - Current Oncology, 2012 - ncbi.nlm.nih.gov
Since the year 2000, tremendous progress has been made in the understanding of
castration-resistant prostate cancer (crpc), a disease state now recognized to retain …

Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions

R Leibowitz-Amit, AM Joshua - … oncology (Toronto, Ont …, 2012 - pubmed.ncbi.nlm.nih.gov
Since the year 2000, tremendous progress has been made in the understanding of
castration-resistant prostate cancer (crpc), a disease state now recognized to retain …
[PDF] semanticscholar.org

[PDF][PDF] Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions

R Leibowitz–Amit, AM Joshua - CURRENT ONCOLOGY, 2012 - pdfs.semanticscholar.org
Since the year 2000, tremendous progress has been made in the understanding of
castration-resistant prostate cancer (CRPC), a disease state now recognized to retain …

Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions.

R Leibowitz-Amit, AM Joshua - Current Oncology (Toronto, Ont.), 2012 - europepmc.org
Since the year 2000, tremendous progress has been made in the understanding of
castration-resistant prostate cancer (crpc), a disease state now recognized to retain …

Targeting the androgen receptor in the: management of castration-resistant prostate cancer: rationale, progress, and future directions.

R Leibowitz-Amiti, AM Joshua - Current Oncology, 2012 - search.ebscohost.com
Since the year 2000, tremendous progress has been made in the understanding of
castration-resistant prostate cancer (CRPC), a disease state now recognized to retain …

Targeting the androgen receptor in the: management of castration-resistant prostate cancer: rationale, progress, and future directions.

R Leibowitz-Amiti, AM Joshua - Current Oncology, 2012 - search.ebscohost.com
Since the year 2000, tremendous progress has been made in the understanding of
castration-resistant prostate cancer (CRPC), a disease state now recognized to retain …

Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions.

R Leibowitz-Amit, AM Joshua - Current Oncology (Toronto, Ont.), 2012 - europepmc.org
Since the year 2000, tremendous progress has been made in the understanding of
castration-resistant prostate cancer (crpc), a disease state now recognized to retain …